Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Boundless Bio Inc | BOLD | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.66 | 03:09:31 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.66 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 9.83 - 15.20 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 10.66 | USD |
Boundless Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.32B | 311.79M | - | 0 | -49.43M | -0.16 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Boundless Bio News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/11/2024 | 07:00 | Business Wire | Boundless Bio Announces First Patient Dosed in.. |
| 4/08/2024 | 07:00 | Business Wire | Boundless Bio Presents Preclinical and Clinical.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BOLD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.45 | 11.90 | 9.83 | 10.61 | 146,244 | 0.21 | 2.01% |
| 1 Month | 14.25 | 15.20 | 9.83 | 12.64 | 249,268 | -3.59 | -25.19% |
| 3 Months | 14.25 | 15.20 | 9.83 | 12.64 | 249,268 | -3.59 | -25.19% |
| 6 Months | 14.25 | 15.20 | 9.83 | 12.64 | 249,268 | -3.59 | -25.19% |
| 1 Year | 14.25 | 15.20 | 9.83 | 12.64 | 249,268 | -3.59 | -25.19% |
| 3 Years | 14.25 | 15.20 | 9.83 | 12.64 | 249,268 | -3.59 | -25.19% |
| 5 Years | 41.00 | 60.00 | 9.83 | 46.21 | 672,053 | -30.34 | -74.00% |
Boundless Bio Description
| Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. |
